Citadel Advisors
ARRY

Citadel Advisors’s Array Biopharma Inc ARRY Stock Holding History

Citadel Advisors’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-339,100
Closed -$15.7M – 10179
2019
Q2 		$15.7M Buy
339,100
+284,100
+517% +$7.98M 0.01% 1661
2019
Q1 		$1.34M Buy
55,000
+11,000
+25% +$229K ﹤0.01% 5086
2018
Q4 		$627K Sell
44,000
-31,600
-42% -$479K ﹤0.01% 6056
2018
Q3 		$1.15M Sell
75,600
-48,800
-39% -$748K ﹤0.01% 5300
2018
Q2 		$2.09M Buy
124,400
+37,500
+43% +$597K ﹤0.01% 4045
2018
Q1 		$1.42M Sell
86,900
-19,800
-19% -$317K ﹤0.01% 4268
2017
Q4 		$1.37M Sell
106,700
-25,200
-19% -$287K ﹤0.01% 4179
2017
Q3 		$1.62M Buy
131,900
+1,200
+0.9% +$11.1K ﹤0.01% 3665
2017
Q2 		$1.09M Buy
130,700
+27,700
+27% +$227K ﹤0.01% 3968
2017
Q1 		$921K Buy
103,000
+44,300
+75% +$471K ﹤0.01% 4125
2016
Q4 		$516K Buy
58,700
+400
+0.7% +$2.94K ﹤0.01% 4848
2016
Q3 		$394K Buy
58,300
+24,500
+72% +$94.8K ﹤0.01% 5231
2016
Q2 		$120K Sell
33,800
-9,100
-21% -$29.7K ﹤0.01% 6119
2016
Q1 		$127K Sell
42,900
-9,100
-18% -$27.3K ﹤0.01% 5918
2015
Q4 		$219K Buy
52,000
+24,600
+90% +$112K ﹤0.01% 5692
2015
Q3 		$125K Buy
27,400
+13,500
+97% +$80K ﹤0.01% 6726
2015
Q2 		$100K Sell
13,900
-2,800
-17% -$20.7K ﹤0.01% 7081
2015
Q1 		$123K Buy
16,700
+5,800
+53% +$41.3K ﹤0.01% 6677
2014
Q4 		$52K Buy
10,900
+2,500
+30% +$9.89K ﹤0.01% 7167
2014
Q3 		$30K Buy
8,400
+900
+12% +$3.55K ﹤0.01% 7222
2014
Q2 		$34K Sell
7,500
-14,800
-66% -$61.2K ﹤0.01% 7017
2014
Q1 		$105K Buy
22,300
+10,500
+89% +$52.8K ﹤0.01% 6152
2013
Q4 		$59K Buy
+11,800
New +$64.2K ﹤0.01% 5954

Other funds holding ARRY

ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Citadel Advisors's ARRY Position: Q3 2019 in Review

Citadel Advisors sold out of Array Biopharma Inc (ARRY) in Q3 2019, closing a stake of 4,346,050 shares — an estimated $201M sold.

Citadel Advisors first reported a position in ARRY in Q2 2013 and held it in 24 quarters. The position peaked at $201M in Q2 2019. 1 fund tracked by Wall St. Rank holds ARRY as of Q3 2019.

  • Citadel Advisors reported no remaining Array Biopharma Inc position as of Q3 2019 after selling out during the quarter.
  • Citadel Advisors sold 4,346,050 Array Biopharma Inc shares in Q3 2019, an estimated $201M.
  • Citadel Advisors first reported a position in Array Biopharma Inc in Q2 2013 and held it in 24 quarters.
  • Citadel Advisors's Array Biopharma Inc position peaked at $201M in Q2 2019.
  • 1 fund tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2019.

Based on Citadel Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.